IceCure Medical Ltd. announced that Thomas Hospital of Fairhope, Alabama, part of the Infirmary Health network, has become the first hospital in the state to install its ProSense cryoablation system for breast cancer. The installation was funded by the Thomas Hospital Foundation, the nonprofit arm that supports advanced medical technology acquisitions.
The ProSense system provides a minimally invasive alternative to surgical lumpectomy for low‑risk tumors. Its FDA marketing authorization in October 2025 for women aged 70 and over with tumors 1.5 cm or smaller has opened a new outpatient market. The first procedures are expected to begin in February 2026, with Dr. Katelin Holmes, the hospital’s breast surgeon and co‑director of the National Accreditation Program for Breast Centers, selecting patients.
This deal expands IceCure’s U.S. footprint beyond its existing 20 sites, positioning the company to capture a share of the growing outpatient breast‑cancer market. IceCure’s record ProSense sales in 2025 and the FDA clearance have already driven strong demand, and the Alabama installation signals broader acceptance across regional health systems.
IceCure’s financial performance in 2025 showed revenue of $2.1 million for the nine months ended September 30, down from $2.4 million in the same period in 2024, reflecting a 9% decline. The company remains unprofitable, but record ProSense sales indicate a trajectory toward revenue growth as more hospitals adopt the technology.
Analysts have expressed mixed views on the company’s outlook, reflecting uncertainty about how quickly the broader market will adopt cryoablation technology and how IceCure will manage its current losses.
The Alabama installation underscores IceCure’s strategy to leverage its FDA clearance and expand into new markets. By securing a high‑profile hospital in a regional network, IceCure is positioning itself to accelerate adoption of ProSense across the United States, potentially boosting future revenue and strengthening its competitive moat.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.